# CJC-1295 Research — Mechanism, Phase 1 PK/PD, pulsatility, halted Phase 2, and forensic analytics > A peer-reviewed summary of CJC-1295 research: GHRH-receptor mechanism, DAC bioconjugate pharmacokinetics, the Teichman 2006 Phase 1 data, the Ionescu pulsatility paper, the halted NCT00267527 trial, and recent WADA analytical methodology. What twenty years of published work establishes — and what it explicitly does not. ## The research record, plainly The published science on CJC-1295 is narrower than its online reputation suggests. Two 2006 studies on healthy adults — one measuring pharmacokinetics, one examining whether normal pulsatile growth-hormone release is preserved — are the core of the human evidence base. Both were conducted by the same group, in small cohorts, before the Phase 2 clinical program was halted. What those studies showed: single subcutaneous doses raise growth hormone levels by two to ten times and keep IGF-1 elevated for up to eleven days. The natural rhythmic bursting of growth hormone secretion is preserved, not abolished. A mouse study from the same year confirmed that the compound can substitute for the animal's own growth-hormone-releasing hormone. What those studies did not show: long-term safety, efficacy for any health outcome, or any data beyond short-term pharmacokinetics in healthy volunteers. The Phase 2 trial that might have supplied efficacy data was terminated before those results were published. ## Mechanism: a GHRH receptor agonist on an albumin tether CJC-1295 binds the GHRH receptor (GHRHR), a class-B G-protein-coupled receptor expressed predominantly on somatotroph cells of the anterior pituitary. Activation initiates a Gs-protein, adenylyl-cyclase, cAMP, protein-kinase-A second-messenger cascade that upregulates growth hormone gene transcription and triggers pulsatile GH secretion [1]. Downstream, hepatic IGF-1 (somatomedin C) production rises in response to circulating GH, and IGF-1 becomes the primary biomarker of GH-axis activation [2]. What distinguishes CJC-1295 from native GHRH is the Drug Affinity Complex (DAC) — a maleimidopropionic acid group appended to the C-terminus that undergoes a Michael-addition reaction with the free thiol on Cys34 of circulating serum albumin after subcutaneous injection [1]. The covalent peptide-albumin bioconjugate is sterically shielded from peptidase degradation and from renal clearance. Native GHRH has a plasma half-life of approximately seven minutes; the four protective amino acid substitutions in the modified GRF (1-29) backbone extend that to roughly 30 minutes by resisting DPP-4 cleavage, deamidation, and oxidation [8]; the DAC bioconjugate extends it further still, to between 5.8 and 8.1 days in healthy adults [3]. The pharmacology is therefore not 'a more potent GHRH' but 'a GHRH-equivalent stimulus delivered over days rather than minutes.' That distinction matters for how the compound's effects on the GH/IGF-1 axis present in the literature. ## The Phase 1 record: Teichman 2006 The first and most-cited human pharmacokinetic study on CJC-1295 was published by Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2006 [2]. Healthy adults received single subcutaneous injections at one of four dose levels — 30, 60, 125, or 250 μg/kg — and were followed for plasma GH, IGF-1, and pharmacokinetic parameters across cohorts. The findings, as reported: single-dose mean plasma GH rose two- to ten-fold above baseline and remained elevated for at least six days; mean IGF-1 rose 1.5- to three-fold above baseline and remained elevated for nine to eleven days. Multiple-dose cohorts dosed weekly or biweekly for 28 to 49 days sustained IGF-1 elevation across the dosing window, with no plateau observed within that interval [2]. Mean plasma half-life estimates fell between 5.8 and 8.1 days across dose cohorts [3]. No serious adverse events attributable to study drug were reported in the Phase 1 cohort. The most commonly reported events were injection-site reactions and transient facial flushing — both consistent with documented effects of GHRH receptor agonism. ## Pulsatility preserved: Ionescu and Frohman A second 2006 paper from the same program, by Ionescu and Frohman, addressed a mechanistically important question — whether continuous stimulation by a long-acting GHRH analog would abolish the natural pulsatile secretion of growth hormone, as exogenous recombinant GH effectively does, or whether somatotrophs would continue to fire in discrete pulses against an elevated baseline [6]. The finding was the latter. Single CJC-1295 injections raised basal (trough) GH levels approximately 7.5-fold while mean GH ran about 46% above baseline; pulsatile architecture — discrete GH bursts at characteristic intervals — persisted across the elevated baseline. The authors characterized this as a pharmacologically distinctive profile relative to recombinant GH administration [6]. This pulsatility preservation is the mechanism-level argument frequently invoked for why a GHRH analog might be theoretically preferable to exogenous GH in research contexts. The argument is mechanistic and rests on Phase 1 PK data, not on long-term human efficacy or safety trials, of which none exist. ## GHRH-knockout mouse model: Alba 2006 In the same year, Alba and colleagues published a study of CJC-1295 in GHRH-knockout mice — animals genetically unable to produce endogenous GHRH and consequently growth-impaired [4]. Once-daily subcutaneous injections of 2 μg per mouse for five weeks normalized linear growth, body weight, and lean body composition against untreated knockout controls. Less-frequent dosing at 48-hour and 72-hour intervals produced partial restoration. Pituitary somatotroph proliferation and GH mRNA expression both increased with treatment. The study is the cleanest mechanistic demonstration that CJC-1295 can substitute for endogenous GHRH in a deficient system. It does not establish efficacy for any human indication, but it grounds the molecular pharmacology in a whole-animal phenotype. ## The halted Phase 2: NCT00267527 The only registered Phase 2 trial of CJC-1295 — NCT00267527, sponsored by ConjuChem Biotechnologies and conducted in HIV-associated visceral adiposity — enrolled 192 participants on a weekly subcutaneous dosing schedule [7]. The trial was terminated in October 2006 after a participant died of an acute coronary event approximately two hours after the eleventh weekly dose. An independent safety review attributed the event to pre-existing undiagnosed coronary artery disease and judged it unrelated to study drug. The trial was not restarted. No further sponsor-funded clinical development of CJC-1295 has occurred since. Primary efficacy endpoints on visceral fat, the trial's named outcome, were never published in the peer-reviewed literature [7]. For context on the indication: the closely related FDA-approved GHRH analog tesamorelin produces a 15-20% reduction in visceral adipose tissue over 26 weeks of daily 2 mg subcutaneous dosing in HIV-associated lipodystrophy [14]. That benchmark — established in a separate molecule from the same pharmacological class — is the closest published efficacy reference point for what the CJC-1295 Phase 2 program might have measured, had it run to completion. ## Serum protein signatures: Sackmann-Sala 2009 A 2009 proteomic study by Sackmann-Sala and colleagues analyzed serum samples from eleven healthy young men one week after a single CJC-1295 injection [5]. Five differentially expressed serum proteins were identified: apolipoprotein A1 and transthyretin isoforms decreased; β-hemoglobin, albumin C-terminal fragments, and immunoglobulin fragments increased. The immunoglobulin and albumin-fragment spot correlated linearly with IGF-1 levels, suggesting a candidate biomarker panel for GH/IGF-1 axis activation downstream of GHRH-analog administration. The study is methodological — it identifies serum signatures of GH/IGF-1 axis activation rather than evaluating clinical outcomes — but it remains one of the few peer-reviewed human exposure analyses of CJC-1295 published after the Phase 2 termination. ## Forensic and anti-doping analytics The compound has continued to appear in the analytical chemistry literature, primarily through anti-doping and forensic-identification work. In 2010, Henninge and colleagues at an anti-doping laboratory used liquid chromatography high-resolution tandem mass spectrometry to determine the sequence of an unknown peptide pharmaceutical preparation seized through enforcement channels [9]. The compound was identified as CJC-1295. The paper is one of the first explicit confirmations in the literature that the compound is in distribution through gray-market channels and that confirming the identity of seized material requires sequence-level mass spectrometric analysis. In 2024, Thomas and colleagues published validated nano-LC quadrupole/Orbitrap mass spectrometry methods for screening and confirmation of CJC-1295 and related GHRH synthetic analogs in athlete urine, compliant with WADA technical requirements [11]. The work addresses two persistent analytical challenges — peptide instability through standard sample-preparation workflows and very low urinary concentrations of the parent peptide — and brings routine doping-control detection of CJC-1295 within reach of accredited laboratories. ## Documented patterns of unsupervised use Outside the published clinical literature, observational and qualitative work has documented patterns of CJC-1295 acquisition outside clinical channels. A 2016 netnographic analysis by Van Hout and Hearne of nine online bodybuilding forums and 23 discussion threads documented self-reported female use of CJC-1295 sourced through non-clinical channels [10]. Reported motivations included weight loss, muscle gain, skin appearance, sleep improvement, and injury recovery. The authors documented safety anxieties expressed by users themselves around gender differences in GH pulsatility and around product purity from unregulated sources — concerns the published clinical literature does not address, because no controlled studies of those use patterns exist. A mechanistic rationale frequently invoked in non-clinical discussion is the combination of a GHRH analog with a GHS-R1a (ghrelin receptor) agonist such as ipamorelin. The pharmacological basis for that pairing is documented: Bowers and colleagues demonstrated in 1990 that combined intravenous administration of GHRH and a ghrelin-receptor agonist produces a GH secretory response several-fold larger than either agent alone in healthy adults [15]. That study used native GHRH and GHRP-6, not CJC-1295 and ipamorelin specifically, but the dual-receptor mechanism is the same. ## What the literature does and does not establish The published literature establishes: that CJC-1295 binds GHRHR and activates the documented downstream signaling cascade [1]; that single doses in healthy adults produce sustained GH and IGF-1 elevation lasting days [2]; that the DAC bioconjugate produces a plasma half-life of 5.8 to 8.1 days in humans [3]; that natural pulsatile GH secretion is preserved during continuous stimulation [6]; that the compound normalizes growth in GHRH-knockout mice [4]; that the only Phase 2 program was terminated in 2006 and did not restart [7]; that the compound is distributed through gray-market channels and identifiable by mass spectrometry [9]; and that it is currently restricted from routine 503A compounding [13, 17] and prohibited by WADA at all times [16]. The published literature does not establish: long-term human efficacy for any indication; long-term human safety; comparative effectiveness against any approved therapy; appropriate dosing for any human use; or a published efficacy benchmark on visceral fat, lean mass, sleep architecture, or any other endpoint discussed in non-clinical settings. --- An independent editorial record of what the published literature, the FDA, and WADA say about CJC-1295.